Effect of Quercetin supplementation on women with Polycystic ovary syndrome.

The effect of Quercetin supplementation on plasma level of Resistin and its gene expression in Peripheral blood mononuclear cells and metabolic risk factors in women with Polycystic ovary syndrome.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016082215536N4

Enrollment

Registered

2017-03-04

Start date

2017-01-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Ovary Syndrome. Sclerocystic ovary syndrome Stein-Leventhal syndrome

Interventions

Intervention 1: Intervention group

receive Quercetin supplements 1 Gram daily for 12 weeks as the two tablets of 500 Milligram after 2 main meals (breakfast and lunch) and this supplement should not be taken on an empty stomach. Interv

Treatment - Drugs

Placebo

Intervention group

receive Quercetin supplements 1 Gram daily for 12 weeks as the two tablets of 500 Milligram after 2 main meals (breakfast and lunch) and this supplement should not be taken on an empty stomach.

Placebo group: receive placebo Quercetin for 12 weeks daily

Eligibility

Sex/Gender

Female

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: people with Body Mass Index between 25 to 40; age range of 20 to 40 year; According to the Rotterdam conference have at least 2 of the 3 criteria listed index as the disease is consider; criteria include irregular periods clinical or biochemical Hyperandrogenism and existence of Polycystic ovary base on ultrasound; willingness to cooperate; lack of medication Metformin; Oral contraceptive pill; Antihypertensive drug; lowering blood fat; Anti-inflammatory; Weight-loss drugs. Exclusion criteria: suffering from endocrine and metabolic disease like Hypothyroidism and Hyperthyroidism; Cancer androgen manufacturer; Diabetes mellitus; Adrenal Hyperplasia; Cushing; Ovarian tumors; Hyperprolactinemia; Smoking; Pregnancy; Lactation; Menopause; allergic reaction to the supplement; withdrew the patient from the study cooperation

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Plasma Resistin. Timepoint: Before and after intervention. Method of measurement: Resitin ELISA Kit.	—

Secondary

Measure	Time frame
C-reactive protein. Timepoint: Before and after intervention. Method of measurement: Serum levels of hs-CRP ELISA Kit.;Glucose. Timepoint: Before and after intervention. Method of measurement: Serum ELISA Kit.;Insulin. Timepoint: Before and after intervention. Method of measurement: Serum ELISA kit micro.;Testosterone. Timepoint: Before and after intervention. Method of measurement: Serum Elisa kit.;Progesterone. Timepoint: Before and after intervention. Method of measurement: serum Elisa kit.;Luteinizing hormone. Timepoint: Before and after intervention. Method of measurement: ELISA kit.;Follicle-stimulating hormone. Timepoint: Before and after intervention. Method of measurement: ELISA kit.;Sex Hormone Binding Globulin. Timepoint: Before and after intervention. Method of measurement: IRMA.;Systolic blood pressure. Timepoint: Before and after intervention. Method of measurement: Pressure set.;Diastolic blood pressure. Timepoint: Before and after intervention. Method of measurement: Pressure set.;Resistin level. Timepoint: Before and after intervention. Method of measurement: RT-PCR.;Total cholesterol. Timepoint: Before and after intervention. Method of measurement: Serum total cholesterol concentration turbidometry.;Triglyceride. Timepoint: Before and after intervention. Method of measurement: Serum triglyceride concentrations were enzymatically.;Low-density lipoprotein. Timepoint: Before and after intervention. Method of measurement: LDL-C levels.;High-density lipoprotein. Timepoint: Before and after intervention. Method of measurement: Serum HDL cholesterol concentration.	—

Measure

Time frame

C-reactive protein. Timepoint: Before and after intervention. Method of measurement: Serum levels of hs-CRP ELISA Kit.;Glucose. Timepoint: Before and after intervention. Method of measurement: Serum ELISA Kit.;Insulin. Timepoint: Before and after intervention. Method of measurement: Serum ELISA kit micro.;Testosterone. Timepoint: Before and after intervention. Method of measurement: Serum Elisa kit.;Progesterone. Timepoint: Before and after intervention. Method of measurement: serum Elisa kit.;Luteinizing hormone. Timepoint: Before and after intervention. Method of measurement: ELISA kit.;Follicle-stimulating hormone. Timepoint: Before and after intervention. Method of measurement: ELISA kit.;Sex Hormone Binding Globulin. Timepoint: Before and after intervention. Method of measurement: IRMA.;Systolic blood pressure. Timepoint: Before and after intervention. Method of measurement: Pressure set.;Diastolic blood pressure. Timepoint: Before and after intervention. Method of measurement: Pressure set.;Resistin level. Timepoint: Before and after intervention. Method of measurement: RT-PCR.;Total cholesterol. Timepoint: Before and after intervention. Method of measurement: Serum total cholesterol concentration turbidometry.;Triglyceride. Timepoint: Before and after intervention. Method of measurement: Serum triglyceride concentrations were enzymatically.;Low-density lipoprotein. Timepoint: Before and after intervention. Method of measurement: LDL-C levels.;High-density lipoprotein. Timepoint: Before and after intervention. Method of measurement: Serum HDL cholesterol concentration.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMasoud Khorshidi

Tehran University of Medical Sciences

khorshidi.2065@gmail.com+98 21 8897 4463

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026